经典疗法新突破：提高晚期甲状腺癌的碘摄取率。
A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.
机构信息
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California.
VA Greater Los Angeles Healthcare System, Los Angeles, California.
出版信息
Clin Cancer Res. 2024 Apr 1;30(7):1220-1222. doi: 10.1158/1078-0432.CCR-23-3503.
Abstract
Advanced differentiated thyroid cancer that is resistant to radioactive iodine therapy may become responsive with a unique treatment combination of chloroquine and vorinostat. This treatment was demonstrated in cellular and animal models of thyroid cancer to inhibit endocytosis of the plasma membrane-bound iodine transporter, NIS, and restore iodine uptake. See related article by Read et al., p. 1352.
摘要
对放射性碘治疗有抗性的晚期分化型甲状腺癌，可能会对氯喹和伏立诺他联合治疗产生反应。该治疗方案在甲状腺癌细胞和动物模型中证明能抑制细胞膜结合碘转运体 NIS 的内吞作用，并恢复碘摄取。详见 Read 等人的相关文章，第 1352 页。
相似文献
1
A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.经典疗法新突破：提高晚期甲状腺癌的碘摄取率。
Clin Cancer Res. 2024 Apr 1;30(7):1220-1222. doi: 10.1158/1078-0432.CCR-23-3503.
2
Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.联合伏立诺他和氯喹抑制钠碘同向转运体内吞作用并增强放射性核素摄取体内。
Clin Cancer Res. 2024 Apr 1;30(7):1352-1366. doi: 10.1158/1078-0432.CCR-23-2043.
3
Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.重组人促甲状腺素（rhTSH）辅助放射性碘治疗残留或转移性分化型甲状腺癌。
Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD008302. doi: 10.1002/14651858.CD008302.pub2.
4
Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis.中国晚期放射性碘难治性分化型甲状腺癌患者应用血管内皮生长因子受体抑制剂：一项网络荟萃分析和成本效益分析。
Front Endocrinol (Lausanne). 2022 Jul 14;13:909333. doi: 10.3389/fendo.2022.909333. eCollection 2022.
5
Pregnancy among thyroid cancer survivors: do thyroidectomy and radioactive iodine matter?甲状腺癌幸存者的妊娠情况：甲状腺切除术和放射性碘治疗有影响吗？
Postgrad Med J. 2025 Jun 22;101(1197):636-643. doi: 10.1093/postmj/qgae197.
6
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.氨磷汀用于大剂量放射性碘治疗分化型甲状腺癌时的唾液腺保护
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD007956. doi: 10.1002/14651858.CD007956.pub2.
7
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.卡博替尼对比安慰剂可提高碘难治性分化型甲状腺癌患者的无进展生存期，与既往是否接受血管内皮生长因子受体靶向治疗及肿瘤组织学类型无关：COS-MIC-311 研究的亚组分析。
Thyroid. 2024 Mar;34(3):347-359. doi: 10.1089/thy.2023.0463. Epub 2024 Jan 23.
8
Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer.剖析“癌症之王”：甲状腺癌患者放射性碘相关的颅面副作用。
J Cancer Surviv. 2020 Dec;14(6):847-857. doi: 10.1007/s11764-020-00897-5. Epub 2020 Jun 6.
9
Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.铟-111-奥曲肽闪烁扫描术用于治疗对大剂量碘-131无反应的分化型甲状腺癌转移灶
J Cancer Res Clin Oncol. 2003 May;129(5):287-94. doi: 10.1007/s00432-003-0435-9. Epub 2003 May 15.
10
本文引用的文献
1
Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.联合伏立诺他和氯喹抑制钠碘同向转运体内吞作用并增强放射性核素摄取体内。
Clin Cancer Res. 2024 Apr 1;30(7):1352-1366. doi: 10.1158/1078-0432.CCR-23-2043.
2
Pathogenesis of cancers derived from thyroid follicular cells.甲状腺滤泡细胞来源癌的发病机制。
Nat Rev Cancer. 2023 Sep;23(9):631-650. doi: 10.1038/s41568-023-00598-y. Epub 2023 Jul 12.
3
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.综述文章：晚期分化型甲状腺癌的新治疗方法和耐药潜在机制。
Front Endocrinol (Lausanne). 2023 Jun 26;14:1176731. doi: 10.3389/fendo.2023.1176731. eCollection 2023.
4
Structural insights into the mechanism of the sodium/iodide symporter.钠离子/碘转运体的结构机制研究进展
Nature. 2022 Dec;612(7941):795-801. doi: 10.1038/s41586-022-05530-2. Epub 2022 Dec 14.
5
Basolateral Sorting of the Sodium/Iodide Symporter Is Mediated by Adaptor Protein 1 Clathrin Adaptor Complexes.钠/碘转运体的基底外侧分拣由衔接蛋白 1 网格蛋白衔接复合物介导。
Thyroid. 2022 Oct;32(10):1259-1270. doi: 10.1089/thy.2022.0163. Epub 2022 Aug 16.
6
The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy.碘化钠同向转运体（NIS）作为诊疗基因：其在新型成像模式和非病毒基因治疗中的新作用。
EJNMMI Res. 2022 May 3;12(1):25. doi: 10.1186/s13550-022-00888-w.
7
Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.放射性碘难治性甲状腺癌的新型治疗方法。
Front Endocrinol (Lausanne). 2021 Jul 15;12:720723. doi: 10.3389/fendo.2021.720723. eCollection 2021.
8
Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.分化型甲状腺癌中放射性碘难治性的分子机制：由于信号通路活性改变和钠碘同向转运体（NIS）的细胞内定位改变导致NIS表达受损。
Theranostics. 2021 Apr 15;11(13):6251-6277. doi: 10.7150/thno.57689. eCollection 2021.
9
Radioiodine treatment: an historical and future perspective.放射性碘治疗：历史与未来展望。
Endocr Relat Cancer. 2021 Sep 3;28(10):T121-T124. doi: 10.1530/ERC-21-0037.
10
Treatment of Differentiated Thyroid Carcinomas.分化型甲状腺癌的治疗
Surg Pathol Clin. 2019 Dec;12(4):931-942. doi: 10.1016/j.path.2019.08.003. Epub 2019 Sep 27.
Zotero 插件